Natasha Setia, MD, MS

Chief Heme/Onc and Integrative Oncology Fellow @CityofHope s/p @UCSF @NorthwellHealth @GeisingerCwlth @Georgetown @NYUniversity Views are my own

[#TumorBoardTuesday @TumorBoardTues]

#TumorBoardTuesday
One of the biggest updates at #ASCO26 was on the management of liver only, advanced #HCC

📢Join us Tuesday, 07-21-26 at 8PM ET as @DanengLi & @theGIoncdoc 🗣️the value of EMERALD(s) in HCC?”

RT and bring others into the discussion‼️

[Natasha Setia, MD, MS @theGIoncdoc]

@MPishvaian @TumorBoardTues @DanengLi @IntegrityCE @DanEng Unfortunately, no.

[Natasha Setia, MD, MS @theGIoncdoc]

@TumorBoardTues @DanengLi @IntegrityCE @DanEng #PostTest Q2️⃣ #TumorBoardTuesday
👉🏽 Free CME 🔗 https://t.co/INQrmYnzvN

🧑‍⚕️ A patient with embolization-eligible #HCC is being considered for a bevacizumab-containing TACE regimen

🤔 Which baseline review should be prioritized before treatment❓

[Natasha Setia, MD, MS @theGIoncdoc]

@TumorBoardTues @DanengLi @IntegrityCE @DanEng #PostTest Q1️⃣ #TumorBoardTuesday
👉🏽#CME Eval 🔗 https://t.co/fODoaCviAI
👉🏽ALL CME🔗 https://t.co/INQrmYnzvN

🤔Based on the Ph3 EMERALD-1 (durva+bev+TACE) & LEAP-012 (pembro+lenva+TACE) studies, what do you conclude re: TACE+ICI-based tx vs TACE alone for HCC❓

[Natasha Setia, MD, MS @theGIoncdoc]

@TumorBoardTues @DanengLi @IntegrityCE @DanEng @jgong15 @Ahn_Daniel_Onc @BasselElRayesMD @MallaMidhun @pgholam @MarkYarchoan @marinabaretti @BeauToskichMD @MaenAbdelrahim @UGrewalMD @DrSukeshiArora @GIcancerDoc @Erman_Akkus, @ArndtVogel @HardingJJMD @GImedonc